Chart to Watch: Biopharma dealmaking gains momentum
After a notable pickup toward the end of last year, biopharma M&A and IPO activity have accelerated in 2026. Portfolio Manager Andy Acker discusses how the increase in deal activity mirrors the pace of innovation taking place across biotechnology and its potential implications for the broader healthcare sector.
Source: Bloomberg, as of 30 June 2026. Represents global M&A transactions where the target industry is classified as Biotech & Pharma.
What excites us most isn't necessarily the increase in deal activity, but what it says about innovation across the biotech landscape. We continue to see a broad wave of scientific advances taking shape in areas such as oncology, immunology, rare diseases, and other fields with significant unmet medical need. The pickup in M&A and capital markets activity suggests strategic acquirers and investors increasingly recognize the value of these innovations and their potential to improve patient outcomes.
Key takeaways
- Despite a higher interest-rate backdrop than many expected at the start of the year, the momentum we saw building in biotech deal activity has continued unabated, with both the dollar value and breadth of transactions inflecting higher during the first half of 2026.
- The continued pace of acquisitions highlights biotechnology's important role in driving healthcare innovation. Notably, many deals have targeted small- and mid-cap biotech companies advancing promising clinical programs, an area where we continue to find attractive investment opportunities. With large pharmaceuticals under pressure to replace hundreds of billions of dollars in drug revenues that will lose patent protection in the coming years, we believe demand for differentiated biotech assets should remain strong.
- Beyond M&A, biotech initial public offering (IPO) activity has rebounded, including two of the largest biotech IPOs on record during the second quarter. A healthier funding environment can benefit the broader biopharmaceutical ecosystem, helping support the discovery and development of future medicines while creating opportunities for companies providing the tools and services that enable innovation.
IMPORTANT INFORMATION
Equity securities are subject to risks including market risk. Returns will fluctuate in response to issuer, political and economic developments.
Health care industries are subject to government regulation and reimbursement rates, as well as government approval of products and services, which could have a significant effect on price and availability, and can be significantly affected by rapid obsolescence and patent expirations.
All opinions and estimates in this information are subject to change without notice and are the views of the author at the time of publication. Janus Henderson is not under any obligation to update this information to the extent that it is or becomes out of date or incorrect. The information herein shall not in any way constitute advice or an invitation to invest. It is solely for information purposes and subject to change without notice. This information does not purport to be a comprehensive statement or description of any markets or securities referred to within. Any references to individual securities do not constitute a securities recommendation. Past performance is not indicative of future performance. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.
Whilst Janus Henderson believe that the information is correct at the date of publication, no warranty or representation is given to this effect and no responsibility can be accepted by Janus Henderson to any end users for any action taken on the basis of this information.